Core Viewpoint - Fosun Pharma's stock surged nearly 74% during trading, currently up 49.28% at HKD 1.03, with a trading volume of HKD 10.37 million following the approval of its drug application by the National Medical Products Administration of China [1] Group 1: Drug Approvals - Fosun Pharma's wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., received approval for its "Enzalutamide Soft Capsule" for treating high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) and asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (CRPC) in adult patients after androgen deprivation therapy (ADT) failure [1] - The company also announced that its product, Metformin and Empagliflozin Tablets (I), is expected to win a bid in the recently published results of China's 11th national centralized drug procurement [1] Group 2: Recent Developments - In September, Fosun Pharma disclosed that its "Metformin and Empagliflozin Tablets (I)" received approval from the National Medical Products Administration of China for market launch [1]
港股异动 | 福森药业(01652)盘中涨近74% 恩扎卢胺软胶囊获批上市 二甲双胍恩格列净片拟中选国家集采